264 related articles for article (PubMed ID: 21883033)
1. Pharmacokinetic evaluation of fluconazole in critically ill patients.
Sinnollareddy M; Peake SL; Roberts MS; Playford EG; Lipman J; Roberts JA
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1431-40. PubMed ID: 21883033
[TBL] [Abstract][Full Text] [Related]
2. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
3. Antifungals in the ICU.
Playford EG; Eggimann P; Calandra T
Curr Opin Infect Dis; 2008 Dec; 21(6):610-9. PubMed ID: 18978529
[TBL] [Abstract][Full Text] [Related]
4. Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region.
Hsueh PR; Graybill JR; Playford EG; Watcharananan SP; Oh MD; Ja'alam K; Huang S; Nangia V; Kurup A; Padiglione AA
Int J Antimicrob Agents; 2009 Sep; 34(3):205-9. PubMed ID: 19409759
[TBL] [Abstract][Full Text] [Related]
5. EPICO PROJECT. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non- neutropenic critically ill adult patients.
Epico Project Group
Rev Esp Quimioter; 2013 Jun; 26(2):131-50. PubMed ID: 23817652
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.
Gharibian KN; Mueller BA
Clin Nephrol; 2016 Jul; 86(7):43-50. PubMed ID: 27251341
[TBL] [Abstract][Full Text] [Related]
7. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
[TBL] [Abstract][Full Text] [Related]
8. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit.
Bassetti M; Ansaldi F; Nicolini L; Malfatto E; Molinari MP; Mussap M; Rebesco B; Bobbio Pallavicini F; Icardi G; Viscoli C
J Antimicrob Chemother; 2009 Sep; 64(3):625-9. PubMed ID: 19622536
[TBL] [Abstract][Full Text] [Related]
9. To treat or not to treat--critically ill patients with candiduria.
Hollenbach E
Mycoses; 2008 Sep; 51 Suppl 2():12-24. PubMed ID: 18721329
[TBL] [Abstract][Full Text] [Related]
10. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
[TBL] [Abstract][Full Text] [Related]
11. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
12. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review.
Sinnollareddy M; Peake SL; Roberts MS; Lipman J; Roberts JA
Int J Antimicrob Agents; 2012 Jan; 39(1):1-10. PubMed ID: 21925845
[TBL] [Abstract][Full Text] [Related]
13. [Invasive fungal infection in critically ill patients].
Garnacho-Montero J; Díaz-Martín A; Ruiz-Pérez De Piappón M; García-Cabrera E
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):338-43. PubMed ID: 22503211
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological advances in the treatment of invasive candidiasis.
Deck DH; Guglielmo BJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
[TBL] [Abstract][Full Text] [Related]
15. Épico Project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients.
Zaragoza R; Llinares P; Maseda E; Ferrer R; Rodríguez A;
Rev Iberoam Micol; 2013; 30(3):135-49. PubMed ID: 23727234
[TBL] [Abstract][Full Text] [Related]
16. Anidulafungin in the treatment of patients with invasive candidiasis.
Kett DH; Cubillos GF
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
[TBL] [Abstract][Full Text] [Related]
17. Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.
van der Geest PJ; Rijnders BJ; Vonk AG; Groeneveld AB
Mycoses; 2016 Mar; 59(3):179-85. PubMed ID: 26707572
[TBL] [Abstract][Full Text] [Related]
18. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
19. [Level of evidence for therapeutic drug monitoring of fluconazole].
Venisse N; Le Guellec C
Therapie; 2011; 66(2):97-101. PubMed ID: 21635855
[TBL] [Abstract][Full Text] [Related]
20. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
